O	0	8	Activity
O	9	11	of
B-intervention	12	23	fulvestrant
O	24	27	500
O	28	30	mg
O	31	37	versus
B-control	38	49	anastrozole
O	50	51	1
O	52	54	mg
O	55	57	as
O	58	63	first
O	63	64	-
O	64	68	line
O	69	78	treatment
O	79	82	for
O	83	91	advanced
O	92	98	breast
O	99	105	cancer
O	105	106	:
O	107	114	results
O	115	119	from
O	120	123	the
O	124	129	FIRST
O	130	135	study
O	135	136	.

O	137	139	To
O	140	147	compare
O	148	151	the
O	152	160	clinical
O	161	169	activity
O	170	172	of
O	173	176	the
O	177	181	pure
O	182	194	antiestrogen
O	195	206	fulvestrant
O	207	209	at
O	210	213	500
O	214	216	mg
O	216	217	/
O	217	219	mo
O	220	221	(
O	221	227	double
O	228	231	the
O	232	240	approved
O	241	245	dose
O	245	246	)
O	247	251	with
O	252	255	the
O	256	265	aromatase
O	266	275	inhibitor
O	276	287	anastrozole
O	288	290	as
O	291	296	first
O	296	297	-
O	297	301	line
O	302	311	endocrine
O	312	319	therapy
O	320	323	for
B-eligibility	324	332	advanced
I-eligibility	333	340	hormone
I-eligibility	341	349	receptor
I-eligibility	349	350	-
I-eligibility	350	358	positive
I-eligibility	359	365	breast
I-eligibility	366	372	cancer
I-eligibility	373	375	in
I-eligibility	376	390	postmenopausal
I-eligibility	391	396	women
O	396	397	.

O	398	403	FIRST
O	404	405	(
O	405	416	Fulvestrant
O	417	422	First
O	422	423	-
O	423	427	Line
O	428	433	Study
O	434	443	Comparing
O	444	453	Endocrine
O	454	464	Treatments
O	464	465	)
O	466	468	is
O	469	470	a
O	471	476	phase
O	477	479	II
O	479	480	,
O	481	491	randomized
O	491	492	,
O	493	497	open
O	497	498	-
O	498	503	label
O	503	504	,
O	505	516	multicenter
O	517	522	study
O	523	525	of
O	526	527	a
O	528	539	fulvestrant
O	540	544	high
O	544	545	-
O	545	549	dose
O	550	551	(
O	551	553	HD
O	553	554	)
O	555	562	regimen
O	563	564	(
O	564	567	500
O	568	570	mg
O	570	571	/
O	571	573	mo
O	574	578	plus
O	579	582	500
O	583	585	mg
O	586	588	on
O	589	592	day
O	593	595	14
O	596	598	of
O	599	604	month
O	605	606	1
O	606	607	)
O	608	614	versus
O	615	626	anastrozole
O	627	628	(
O	628	629	1
O	630	632	mg
O	632	633	/
O	633	634	d
O	634	635	)
O	635	636	.

O	637	640	The
O	641	648	primary
O	649	657	efficacy
O	658	661	end
O	662	667	point
O	668	671	was
B-outcome-Measure	672	680	clinical
I-outcome-Measure	681	688	benefit
I-outcome-Measure	689	693	rate
I-outcome-Measure	694	695	(
I-outcome-Measure	695	698	CBR
I-outcome-Measure	698	699	)
O	699	700	,
O	701	708	defined
O	709	711	as
O	712	715	the
O	716	726	proportion
O	727	729	of
O	730	738	patients
O	739	751	experiencing
O	752	754	an
O	755	764	objective
O	765	773	response
O	774	775	(
O	775	777	OR
O	777	778	)
O	779	781	or
O	782	788	stable
O	789	796	disease
O	797	800	for
O	801	802	>
O	803	805	or
O	806	807	=
O	808	810	24
O	811	816	weeks
O	816	817	.

O	818	821	The
O	822	829	primary
O	830	838	analysis
O	839	842	was
O	843	852	performed
O	853	854	6
O	855	861	months
O	862	867	after
O	868	871	the
O	872	876	last
O	877	884	patient
O	885	888	was
O	889	897	randomly
O	898	906	assigned
O	906	907	.

B-outcome	908	911	CBR
O	912	915	was
O	916	923	similar
O	924	927	for
O	928	939	fulvestrant
O	940	942	HD
O	943	944	(
O	944	945	n
O	946	947	=
B-iv-bin-abs	948	951	102
O	951	952	)
O	953	956	and
O	957	968	anastrozole
O	969	970	(
O	970	971	n
O	972	973	=
B-cv-bin-abs	974	977	103
O	977	978	)
O	978	979	,
B-iv-bin-percent	980	982	72
I-iv-bin-percent	982	983	.
I-iv-bin-percent	983	984	5
I-iv-bin-percent	984	985	%
O	986	987	v
B-cv-bin-percent	988	990	67
I-cv-bin-percent	990	991	.
I-cv-bin-percent	991	992	0
I-cv-bin-percent	992	993	%
O	993	994	,
O	995	1007	respectively
O	1008	1009	(
O	1009	1013	odds
O	1014	1019	ratio
O	1019	1020	,
O	1021	1022	1
O	1022	1023	.
O	1023	1025	30
O	1025	1026	;
O	1027	1029	95
O	1029	1030	%
O	1031	1033	CI
O	1033	1034	,
O	1035	1036	0
O	1036	1037	.
O	1037	1039	72
O	1040	1042	to
O	1043	1044	2
O	1044	1045	.
O	1045	1047	38
O	1047	1048	;
O	1049	1050	P
O	1051	1052	=
O	1053	1054	.
O	1054	1057	386
O	1057	1058	)
O	1058	1059	.

B-outcome	1060	1069	Objective
I-outcome	1070	1078	response
I-outcome	1079	1083	rate
I-outcome	1084	1085	(
I-outcome	1085	1088	ORR
I-outcome	1088	1089	)
O	1090	1093	was
O	1094	1098	also
O	1099	1106	similar
O	1107	1114	between
O	1115	1125	treatments
O	1125	1126	:
O	1127	1138	fulvestrant
O	1139	1141	HD
O	1141	1142	,
B-iv-bin-percent	1143	1145	36
I-iv-bin-percent	1145	1146	.
I-iv-bin-percent	1146	1147	0
I-iv-bin-percent	1147	1148	%
O	1148	1149	;
O	1150	1161	anastrozole
O	1161	1162	,
B-cv-bin-percent	1163	1165	35
I-cv-bin-percent	1165	1166	.
I-cv-bin-percent	1166	1167	5
I-cv-bin-percent	1167	1168	%
O	1168	1169	.

B-outcome	1170	1174	Time
I-outcome	1175	1177	to
I-outcome	1178	1189	progression
I-outcome	1190	1191	(
I-outcome	1191	1194	TTP
I-outcome	1194	1195	)
O	1196	1199	was
O	1200	1213	significantly
O	1214	1220	longer
O	1221	1224	for
O	1225	1236	fulvestrant
O	1237	1243	versus
O	1244	1255	anastrozole
O	1256	1257	(
O	1257	1263	median
O	1264	1267	TTP
B-iv-cont-median	1268	1271	not
I-iv-cont-median	1272	1279	reached
O	1280	1283	for
O	1284	1295	fulvestrant
O	1296	1298	HD
O	1299	1300	v
B-cv-cont-median	1301	1303	12
I-cv-cont-median	1303	1304	.
I-cv-cont-median	1304	1305	5
I-cv-cont-median	1306	1312	months
O	1313	1316	for
O	1317	1328	anastrozole
O	1328	1329	;
O	1330	1336	hazard
O	1337	1342	ratio
O	1342	1343	,
O	1344	1345	0
O	1345	1346	.
O	1346	1348	63
O	1348	1349	;
O	1350	1352	95
O	1352	1353	%
O	1354	1356	CI
O	1356	1357	,
O	1358	1359	0
O	1359	1360	.
O	1360	1362	39
O	1363	1365	to
O	1366	1367	1
O	1367	1368	.
O	1368	1370	00
O	1370	1371	;
O	1372	1373	P
O	1374	1375	=
O	1376	1377	.
O	1377	1381	0496
O	1381	1382	)
O	1382	1383	.

B-outcome	1384	1392	Duration
I-outcome	1393	1395	of
I-outcome	1396	1398	OR
I-outcome	1399	1402	and
I-outcome	1403	1405	CB
O	1406	1410	also
O	1411	1422	numerically
O	1423	1430	favored
O	1431	1442	fulvestrant
O	1443	1445	HD
O	1445	1446	.

O	1447	1451	Both
O	1452	1462	treatments
O	1463	1467	were
B-outcome	1468	1472	well
I-outcome	1473	1482	tolerated
O	1482	1483	,
O	1484	1488	with
O	1489	1491	no
O	1492	1503	significant
O	1504	1515	differences
O	1516	1518	in
O	1519	1522	the
O	1523	1532	incidence
O	1533	1535	of
O	1536	1548	prespecified
B-outcome	1549	1556	adverse
I-outcome	1557	1563	events
O	1563	1564	.

O	1565	1570	First
O	1570	1571	-
O	1571	1575	line
O	1576	1587	fulvestrant
O	1588	1590	HD
O	1591	1594	was
O	1595	1597	at
O	1598	1603	least
O	1604	1606	as
O	1607	1616	effective
O	1617	1619	as
O	1620	1631	anastrozole
O	1632	1635	for
O	1636	1639	CBR
O	1640	1643	and
O	1644	1647	ORR
O	1648	1651	and
O	1652	1655	was
O	1656	1666	associated
O	1667	1671	with
O	1672	1685	significantly
O	1686	1692	longer
O	1693	1696	TTP
O	1696	1697	.

O	1698	1709	Fulvestrant
O	1710	1712	HD
O	1713	1716	was
O	1717	1726	generally
O	1727	1731	well
O	1732	1741	tolerated
O	1741	1742	,
O	1743	1747	with
O	1748	1749	a
O	1750	1756	safety
O	1757	1764	profile
O	1765	1772	similar
O	1773	1775	to
O	1776	1780	that
O	1781	1783	of
O	1784	1795	anastrozole
O	1795	1796	.
